N-Acetyl Selank

Tuftsin-derived heptapeptide with structural modifications that resist enzymatic degradation. Modulates GABA-A receptor complex, increases enkephalin levels in limbic system, and influences serotonin metabolism.

N-Acetyl-Selank is an acetylated derivative of selank (TKPRPGP), a synthetic heptapeptide anxiolytic developed from a tuftsin-based sequence; N-acetylation at the N-terminus is proposed to improve resistance to enzymatic degradation and potentially alter blood-brain barrier permeability relative to the parent compound, with the expectation of enhanced CNS bioavailability and duration of action. The pharmacological rationale derives from the parent compound selank, which acts through GABAergic, serotonergic, and enkephalinergic pathways to produce anxiolytic and nootropic effects in preclinical models and limited Russian human clinical studies; N-acetyl-selank is presumed to retain similar receptor interactions with modified pharmacokinetics. No publications indexed in PubMed specifically examine N-acetyl-selank as a distinct compound; no human clinical trials, independent preclinical studies, or pharmacokinetic comparisons with the parent selank exist in the indexed scientific literature, representing a complete absence of specific evidence for this analog beyond its structural modification. N-Acetyl-Selank has no FDA approval and no approved indication in any jurisdiction; it is available through research chemical suppliers as a purported improvement on selank, but its pharmacological properties, safety profile, and clinical utility in humans are entirely uncharacterized as a distinct compound.